New asthma drug IBI3002 tested in first human trial
NCT ID NCT06213844
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a single dose of the experimental drug IBI3002 in 52 healthy volunteers and people with mild to moderate asthma. The main goal was to check safety and how the body processes the drug. Researchers monitored side effects and drug levels in the blood over five weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI3002
What this could lead to
If successful, this could point toward a new treatment option for asthma that helps control symptoms.
What could go wrong
This is a very early Phase 1 trial with only 52 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia